Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Acute myeloid leukemia (AML) is an aggressive cancer of white blood cells with few effective targeted therapies available to treat it.
Researchers found that the shape of fingerprints is determined by limb development genes instead of skin patterning genes, in the most thorough analysis to date.
Scientists have found a way to prove that biochemical signals sent from cell to cell play an important role in determining how those cells develop.
Researchers recently identified a new role of the protein tBID, which was to date linked to the regulatory role in cancer and cell death. But tBID also directly mediates apoptosis (controlled cell death).
Metabolic reprogramming, accepted as a hallmark of cancer, might indicate a vulnerability to be used by targeted cancer therapy.
In the late 1980s, scientists developed a revolutionary approach to treating acute myeloid leukemia (AML), a type of blood cancer. Called differentiation therapy, it amounted to a bona fide cure for many patients.
In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.
A group of researchers recently unearthed vital information on how gene expression is orchestrated.
University of Delaware biochemist Jeff Mugridge is trying to figure out how so-called mRNA eraser enzymes work in our cells, why those erasers can sometimes misbehave and lead to cancer, and how science can pave the way for possible solutions to this problem.
Pharmaceuticals commonly available on the market are developed by linking together rings of molecules to generate drugs that treat conditions like depression.
Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.
MIT biologists have answered an important biological question: Why do cells control their size? Cells of the same type are strikingly uniform in size, while cell size differs between different cell types. This raises the question of whether cell size is important for cellular physiology.
Even within a single patient with cancer, there is a vast diversity of individual tumor cells, which display distinct behaviors related to growth, metastasis, and responses to chemotherapy.
Inositol is a sugar required for cells to survive. Most cells either get it from the bloodstream or make it themselves. Since there is plenty of inositol available, some cancer cells decide to stop making it.
More than 40,000 allogeneic hematopoietic stem cell transplants are carried out worldwide every year, mostly for patients suffering from leukemia or other diseases of the hematopoietic system.
Recent research enhances the understanding of certain cancers and complex congenital disorders.
One in five cancers affects lymph nodes and blood cells resulting in lymphomas and leukemias, respectively.
Researchers carried out the first extensive investigation of the formation of the blood and immune systems in the prenatal bone marrow.
Researchers elucidate why certain drugs, in clinical trials, for treating a kind of acute myeloid leukemia often fail and revealed a means to restore their efficacy.
Stem cell transplants do not lead to changes in the DNA of the donor cells. That's according to a new study, which provides important evidence for the safety of this procedure.